Zealand Pharma Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
578
- Stock Symbol
-
ZEAL
- Investments
-
2
- Share Price
-
$31.22
- (As of Thursday Closing)
Zealand Pharma General Information
Description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Contact Information
Website
www.zealandpharma.comCorporate Office
- Sydmarken 11
- 2860 Soborg
- Denmark
Corporate Office
- Sydmarken 11
- 2860 Soborg
- Denmark
Zealand Pharma Timeline
Zealand Pharma Stock Performance
As of 19-Nov-2026, Zealand Pharma’s stock price is $31.22. Its current market cap is $2.07B with 66.3M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $31.22 | $32.60 | $31.22 - $85.89 | $2.07B | 66.3M | 404K | $6.91 |
Zealand Pharma Financials Summary
As of 30-Sep-2026, Zealand Pharma has a trailing 12-month revenue of $715M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 616,395 | 2,692,632 | 5,937,273 | 3,016,784 |
| Revenue | 714,888 | 1,392,231 | 9,094 | 49,745 |
| EBITDA | 459,009 | 1,019,548 | (173,078) | (102,057) |
| Net Income | 480,443 | 975,258 | (156,490) | (102,125) |
| Total Assets | 2,948,744 | 2,508,106 | 1,326,190 | 293,973 |
| Total Debt | 73,423 | 63,811 | 54,657 | 17,702 |
Zealand Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Zealand Pharma Comparisons
Industry
Financing
Details
Zealand Pharma Competitors (82)
One of Zealand Pharma’s 82 competitors is Aclaris Therapeutics, a Formerly VC-backed company based in Wayne, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aclaris Therapeutics | Formerly VC-backed | Wayne, PA | ||||
| NewAmsterdam Pharma | Formerly VC-backed | Aventura, FL | ||||
| Protagonist Therapeutics | Formerly VC-backed | Newark, CA | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX | ||||
| MBX Biosciences | Formerly VC-backed | Carmel, IN |
Zealand Pharma Signals
Zealand Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Zealand Pharma Acquisitions (2)
Zealand Pharma’s most recent deal was a Merger/Acquisition with Valeritas Holdings for . The deal was made on 02-Apr-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Valeritas Holdings | 02-Apr-2020 | Merger/Acquisition | Drug Delivery | ||
| Encycle Therapeutics | 22-Oct-2019 | Merger/Acquisition | Drug Discovery |
Zealand Pharma ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
26.86 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Zealand Pharma Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Zp Holding Spv | Soeborg, Denmark | 2014 | |
| V-Go Insulin Delivery Device | Glostrup, Denmark |
Zealand Pharma FAQs
-
When was Zealand Pharma founded?
Zealand Pharma was founded in 1998.
-
Where is Zealand Pharma headquartered?
Zealand Pharma is headquartered in Soborg, Denmark.
-
What is the size of Zealand Pharma?
Zealand Pharma has 578 total employees.
-
What industry is Zealand Pharma in?
Zealand Pharma’s primary industry is Drug Discovery.
-
Is Zealand Pharma a private or public company?
Zealand Pharma is a Public company.
-
What is Zealand Pharma’s stock symbol?
The ticker symbol for Zealand Pharma is ZEAL.
-
What is the current stock price of Zealand Pharma?
As of 19-Nov-2026 the stock price of Zealand Pharma is $31.22.
-
What is the current market cap of Zealand Pharma?
The current market capitalization of Zealand Pharma is $2.07B.
-
What is Zealand Pharma’s current revenue?
The trailing twelve month revenue for Zealand Pharma is $715M.
-
Who are Zealand Pharma’s competitors?
Aclaris Therapeutics, NewAmsterdam Pharma, Protagonist Therapeutics, Rein Therapeutics, and MBX Biosciences are some of the 82 competitors of Zealand Pharma.
-
What is Zealand Pharma’s annual earnings per share (EPS)?
Zealand Pharma’s EPS for 12 months was $6.91.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process